Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review

Ebenezer Oloyede*, Ivana Clark*, Shubhra Mace*, Eromona Whiskey* and David Taylor* and David Taylor

Abstract: Only about 50% of patients with treatment-resistant schizophrenia respond to clozapine, and many more patients continue to experience ongoing and prominent negative symptoms. These negative symptoms, for which there are limited pharmacological options, may represent the greatest barrier to functional recovery. Cariprazine is a novel antipsychotic drug that is a partial agonist at dopamine D2 and D3 receptors with preferential binding to the D3 receptor, antagonism of 5HT2A receptors, and partial agonism at 5HT1A receptors. Cariprazine is currently licenced for the treatment of schizophrenia in Europe and the United States and has also been approved for bipolar disorder in the United States. There is a limited body of evidence to suggest clinical effectiveness as an augmentation strategy for negative symptoms in those treated with clozapine. In this case series, we present five cases of successful treatment of negative symptoms by clozapine combined with cariprazine in treatment-resistant psychosis.

Keywords: augmentation, cariprazine, clozapine

Introduction
Clozapine is a second-generation (‘atypical’) antipsychotic and dibenzodiazepine, with efficacy in treatment-resistant schizophrenia (TRS) – a failure to adequately respond to successive trials of two non-clozapine antipsychotics for 4–6 weeks.1 Since the landmark study by Kane et al.,2 clozapine has been regarded as the most effective antipsychotic for treating positive symptoms, preventing suicidal ideation and reducing the frequency and duration of hospital stays.3–5 Despite this, up to 60% of patients treated with clozapine monotherapy will not respond or only partially respond to treatment.6 Important factors that may influence response to clozapine treatment and the need for augmentation strategies include clozapine/norclozapine plasma levels, pharmacogenetics or changes in smoking status.7,8 Management of these patients has remained a persistent public health problem.9–11

A particularly challenging symptom domain is the alleviation of negative and cognitive symptoms in schizophrenia, associated with significant long-term morbidity, poor functional outcomes and high rates of disability, of which clozapine has shown limited efficacy against.12,13 Because of this, considerable focus has been placed on augmentation strategies for partial responders to clozapine, although compelling evidence for a particular intervention is lacking.14 A class of medication that has attracted interest of late is the partial dopamine agonists, such as cariprazine.

Cariprazine is a novel antipsychotic, licenced for the treatment of schizophrenia in adults in the United Kingdom since 2018. It is also approved for treating manic, mixed and depressive episodes in bipolar I in the United States. Cariprazine exerts partial agonism at D2 and D3 receptors, with high selectivity for the D3 receptor. It also has partial agonist activity at serotonin 5-HT1A receptors (Table 1).15 Cariprazine is distinct from other antipsychotics in that it has a high preferential affinity for the D3 receptor, which is thought to be important in modulating mood and cognition.16

Correspondence to: David Taylor Pharmacy Department, South London and Maudsley NHS Foundation Trust, London SE5 8AZ, UK Institute of Pharmaceutical Science, King’s College London, London, UK david.taylor@slam.nhs.uk Ebenezer Oloyede Pharmacy Department, South London and Maudsley NHS Foundation Trust, London, UK Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK Ivana Clark Shubhra Mace Eromona Whiskey Pharmacy Department, South London and Maudsley NHS Foundation Trust, London, UK, Institute of Pharmaceutical Science, King’s College London, London, UK. *Joint first authors.

*Joint first authors.
Furthermore, some authors consider cariprazine as a potential ‘oral depot’ because of its long half-life (~2 days); however, this is yet to be evaluated in the literature.17 Active metabolites include desmethyl-cariprazine and didesmethyl-cariprazine, the latter of which has a much longer half-life than cariprazine.18 Reported adverse drug effects include insomnia, akathisia, constipation, nausea and vomiting.19 Efficacy has been demonstrated in several short-term randomised controlled trials (RCTs) and a double-blinded extension study.20–25 In a RCT study of patients with predominantly negative symptoms, the effect of cariprazine on negative symptoms was superior to risperidone.26 Further studies have also suggested good outcomes on cognitive functioning, the mechanisms of which remain unelucidated.27 There has been limited exploration in the literature of how cariprazine fares as an augmentation strategy in TRS. Preliminary work has suggested its effectiveness and safety in a small cohort of such patients.28

In this article, we report on five successful cases of clozapine augmentation with cariprazine to alleviate negative symptoms in TRS. In all cases, TRS was defined according to TRIPP criteria.29

### Case studies

#### Case 1
The patient is a Eastern European 34-year-old female with a diagnosis of paranoid schizophrenia. Her first contact with psychiatric services was in her late 20s, where she presented with paranoid persecutory beliefs, auditory hallucinations (command type – asking her to end her life) and negative symptoms (blunted affect, emotional/social withdrawal in absence of clear depressive episode), which were interfering with her social and academic functioning. Prior to this she was prescribed alprazolam for anxiety for approximately 3 years. There was no notable family history. However, regular cannabis use in her adolescents up to first presentation and occasional ecstasy use were reported. The patient had sequential trials with aripiprazole (up to 10 mg for 6 weeks), amisulpride (up to 400 mg for 8 weeks), quetiapine (up to 300 mg for 7 months), and olanzapine (up to 20 mg for 6 weeks) with treatment only achieving partial response.

Given the lack of response to treatment and the patient’s frequent and severe decompensations, it was decided to admit her and begin treatment with clozapine 2 years later. Clozapine was titrated up to a dose of 300 mg at night, achieving a plasma concentration of 0.52 mg/L. Reported adverse effects included constipation, weight gain (+12 kg), hypersalivation and tachycardia, in which she received concomitant senna, metformin, pirenzepine and bisoprolol treatment. The patient demonstrated improvement in positive symptoms with clozapine treatment, but her negative symptoms persisted despite reported compliance. The patient was thereby initiated on lurasidone up to a dose of 74 mg daily to augment clozapine after 11 months of monotherapy. At this time, her positive and negative syndrome scale (PANSS) score was 80 (positive scale = 20; negative scale = 23; and general psychopathology = 37). She also scored 50 on the Global Assessment of Functioning (GAF) scale. Given the lack of clinical response to treatment, lurasidone was discontinued after 2 months. The dose of clozapine was subsequently increased to 350 mg to address residual symptoms, with a recorded PANSS score of 66 (positive scale = 15, negative scale = 20, general psychopathology = 31). Her GAF score increased to 65. After a few months, the patient requested for a dose reduction of clozapine due to persistent sedation and weight gain. Her clozapine blood level at the time was 0.65 mg/L. The dose was therefore reduced to 275 mg daily.

In August 2019, the patient’s clozapine was augmented with cariprazine at a starting dose of 1.5

| Receptor | Cariprazine (nM Ki) | Clozapine (nM Ki) |
|----------|---------------------|------------------|
| D₃       | 0.085*              |                  |
| D₂L      | 0.49*               |                  |
| 5-HT₂B   | 0.58                |                  |
| D₂S      | 0.69*               |                  |
| 5-HT₁A   | 2.6*                | 120              |
| 5-HT₂A   | 18.8                | 5.4              |
| H₁       | 23.2                | 1.1              |
| 5-HT₇    | 111.0               |                  |
| HT₂C     | 134.0               | 9.4              |
| α₁       | 155.0               | 1.6              |

*Partial agonist.

Her first contact with psychiatric services was in her late 20s, where she presented with paranoid persecutory beliefs, auditory hallucinations (command type – asking her to end her life) and negative symptoms (blunted affect, emotional/social withdrawal in absence of clear depressive episode), which were interfering with her social and academic functioning. Prior to this she was prescribed alprazolam for anxiety for approximately 3 years. There was no notable family history. However, regular cannabis use in her adolescents up to first presentation and occasional ecstasy use were reported. The patient had sequential trials with aripiprazole (up to 10 mg for 6 weeks), amisulpride (up to 400 mg for 8 weeks), quetiapine (up to 300 mg for 7 months), and olanzapine (up to 20 mg for 6 weeks) with treatment only achieving partial response.

Given the lack of response to treatment and the patient’s frequent and severe decompensations, it was decided to admit her and begin treatment with clozapine 2 years later. Clozapine was titrated up to a dose of 300 mg at night, achieving a plasma concentration of 0.52 mg/L. Reported adverse effects included constipation, weight gain (+12 kg), hypersalivation and tachycardia, in which she received concomitant senna, metformin, pirenzepine and bisoprolol treatment. The patient demonstrated improvement in positive symptoms with clozapine treatment, but her negative symptoms persisted despite reported compliance. The patient was thereby initiated on lurasidone up to a dose of 74 mg daily to augment clozapine after 11 months of monotherapy. At this time, her positive and negative syndrome scale (PANSS) score was 80 (positive scale = 20; negative scale = 23; and general psychopathology = 37). She also scored 50 on the Global Assessment of Functioning (GAF) scale. Given the lack of clinical response to treatment, lurasidone was discontinued after 2 months. The dose of clozapine was subsequently increased to 350 mg to address residual symptoms, with a recorded PANSS score of 66 (positive scale = 15, negative scale = 20, general psychopathology = 31). Her GAF score increased to 65. After a few months, the patient requested for a dose reduction of clozapine due to persistent sedation and weight gain. Her clozapine blood level at the time was 0.65 mg/L. The dose was therefore reduced to 275 mg daily.

In August 2019, the patient’s clozapine was augmented with cariprazine at a starting dose of 1.5

| Table 1. Receptor binding affinities.26. |
|-----------------|-----------------|
| **Receptor**    | **Cariprazine (nM Ki)** | **Clozapine (nM Ki)** |
| D₃               | 0.085*           |                  |
| D₂L              | 0.49*            |                  |
| 5-HT₂B           | 0.58             |                  |
| D₂S              | 0.69*            |                  |
| 5-HT₁A           | 2.6*             | 120              |
| 5-HT₂A           | 18.8             | 5.4              |
| H₁               | 23.2             | 1.1              |
| 5-HT₇            | 111.0            |                  |
| HT₂C             | 134.0            | 9.4              |
| α₁               | 155.0            | 1.6              |

*Partial agonist.
mg daily to alleviate residual negative symptoms. The patient’s baseline scale for the assessment of negative symptoms (SANS) score was 50. The dose of cariprazine was eventually increased to 3 mg 5 months later due to self-reported intrusive thoughts. No adverse events were noted and her body weight remained unchanged. After 6 months of combined treatment, the patient displayed a fuller affect, an improvement in function and a reduction in residual positive symptoms. Her improved motivation enabled her to start a job as a dog walker and take up driving lessons. After 12 months of combination therapy her SANS score reduced to 22, equivalent to a 56% reduction. (According to Van Erp et al., this broadly equates to a PANSS negative scale score of 15.)

Case 2
The patient is a 60-year-old white British female with a diagnosis of paranoid schizophrenia and depression. Her first contact with psychiatric services was during early adulthood, where she presented with psychotic symptoms and prominent negative symptoms (self-neglect, confusion, apathy and ambivalence). After multiple admissions and unsuccessful trials of various antipsychotics including risperidone (up to 8 mg for 1 year), fluphenazine (37.5 mg every 2 weeks), chlorpromazine (up to 200 mg for 2 years), haloperidol (up to 15 mg for 3 years) the patient was stabilised on clozapine 325 mg in the late 90s. She was a heavy smoker and dependent on alcohol. Despite a reduction in positive symptoms, she continued to experience depressive and negative symptoms. To alleviate this, the patient was prescribed citalopram for 4 years.

The patient’s last admission was 10 years after following a 2-week deterioration in mental state reported by her daughter with typical signs of relapse: self-neglect, poor oral intake and isolative behaviour. There had been a recent reduction in clozapine to 275 mg daily due to a high plasma level of 0.83 mg/L after the patient stopped smoking. During this admission, she presented with cognitive and negative symptoms of psychosis including distractibility, thought block, confusion, apathy and ambivalence. The patient’s antidepressant was switched to venlafaxine up to 75 mg and sodium valproate was initiated as she showed minimal response on citalopram. She was eventually discharged on clozapine 275 mg, venlafaxine MR 225 mg and sodium valproate MR 800 mg daily. She was followed up by the home treatment team, where her clozapine dose was reduced further to 250 mg daily due to clozapine plasma level of 0.77 mg/L.

To address prominent negative symptoms, cariprazine 1.5 mg was added as an augmentation strategy. Her SANS score was 63. No adverse events were noted. The patient’s weight reduced from 90 to 84 kg by October 2019. After 6 months of combined treatment, the patient showed further improvements and showed better engagement with medical staff. At this time, her SANS score was 37, equivalent to a 41% reduction.

Case 3
The patient is a 23-year-old Asian British male with a diagnosis of paranoid schizophrenia. His first contact with psychiatric services during early adulthood, where he presented with paranoid delusions, social isolation and irritability. He was arrested and detained under section 2 of the Mental Health Act (the legal framework for the assessment and treatment of a mental health disorders in the United Kingdom) after allegedly damaging property at his family home and reported aggression and inappropriate sexual remarks towards family members. There was no notable family history and previous criminal convictions. However, regular cannabis use from adolescent up to first presentation were reported. The patient had sequential trials with aripiprazole (up to 20 mg for 1 month), aripiprazole once monthly (400 mg for 2 months) olanzapine (up to 20 mg for 7 weeks), risperidone (up to 6 mg for 2 months), paliperidone palmitate (100 mg for 4 months) and haloperidol decanoate (100 mg every 4 weeks for 8 months) with treatment only achieving partial response.

Given the lack of response to treatment and the patient’s frequent and severe decompensations, clozapine treatment was initiated. Clozapine was titrated up to a dose of 325 mg at night, achieving a plasma concentration of 0.74 mg/L. Reported adverse effects included tachycardia and hypersalivation, in which he received concomitant bisoprolol and hyoscine hydrobromide treatment. The patient demonstrated improvement in positive symptoms with clozapine treatment, but his negative symptoms persisted.

To address prominent negative symptoms, cariprazine 1.5 mg was added as an augmentation strategy 3 months after clozapine initiation. His
SANS score was 60. No adverse events were noted. The patient’s weight remained unchanged. After 12 months of combined treatment, the patient displayed an improvement in function and showed better engagement with family. At this time, his SANS score was 15 equivalent to a 75% reduction.

Case 4
This was a 51-year-old white British male with a diagnosis of schizoaffective disorder, depressive type. His first contact with psychiatric services was in his late 20s, where he presented with persecutory delusions and suicidal thoughts. There were notes of family history of schizophrenia in first degree relatives. Overdose attempts were reported in his early 20s. Furthermore, 15 years later, the patient was diagnosed with an eating disorder by his community team due to a persistent liquid only diet and regularly inducing vomiting with secondary paralytic ileus, acute renal failure and severe oesophagitis. However, it was unclear whether this was neurotic or psychotic in nature. After multiple admissions and unsuccessful trials of various antipsychotics, including amisulpride (for 4 months), quetiapine and olanzapine (for 9 weeks), the patient was stabilised on clozapine 600 mg. His clozapine blood level at the time was 0.46 mg/L. Despite a reduction in positive symptoms, there remained a predominance of negative symptoms and suicidal ideation.

After a year, the patient was initiated on mirtazapine 15 mg daily after he attempted suicide. This was eventually increased to 45 mg daily in addition to cognitive behavioural therapy after a relapse triggered by cuts in his welfare benefits.

To address prominent negative symptoms, cariprazine 1.5 mg daily was added 10 years later. His SANS score was 88. No adverse events were noted and the patient’s weight remained unchanged. After 6 months of combined treatment, the patient displayed a fuller affect and showed better engagement with medical staff. The patient’s residual positive symptoms (command hallucinations) persisted. At this time, his SANS score was 24, equivalent to a 73% reduction. His clozapine blood level at the time was 0.49 mg/L.

Case 5
The patient is a 28-year-old white British male with a diagnosis of paranoid schizophrenia with a background of polysubstance misuse (cannabis, cocaine and mephedrone) since his early teens. His first contact with psychiatric services was during early adulthood, where he presented with somatic and paranoid delusions. He was arrested and detained under section 2 of the Mental Health Act after reported aggression towards family members. The patient had sequential trials with several antipsychotic medications, including amisulpride (for 1 month), risperidone and olanzapine (up to 20 mg for 3 months), with these treatments only resulting in partial response. He was eventually discharged on quetiapine and appeared to achieve stability, securing his own tenancy where he lived with his girlfriend and stepson. However, shortly after discharge he became non-compliant to treatment, leading to unsuccessful trials of aripiprazole and pipothiazine palmitate (100 mg monthly for 3 years).

In the following year he was admitted to a rehabilitation unit after increased auditory hallucinations, anxiety and suicidal ideation linked to polysubstance misuse. During this admission, he was initiated on clozapine treatment (up to 400 mg daily), with a marked improvement in psychotic symptoms, self-care and communication with caregivers and service users. However, the closure of the rehabilitation unit and reallocation to another unit caused the patient to become increasingly withdrawn and eventually refuse clozapine treatment. This led to an increase in positive and negative symptoms, self-neglect and verbal alterations necessitating several admissions to a psychiatric intensive care unit (PICU). Over the next 5 years, the patient was treated with haloperidol decanoate (up to 100 mg monthly for 1 year) and zuclopenthixol decanoate (600 mg weekly), with minimal response. Clozapine treatment was thereby restarted 5 years later, however, sub-therapeutic plasma levels suggested partial compliance. Despite this, improvement in positive symptoms were reported. The patient’s clozapine was augmented with amisulpride (200 mg twice a day for 2 months) in an attempt to alleviate persistent negative symptoms.

The patient was then admitted to the National Psychosis Unit (NPU), a tertiary referral facility specialising in the treatment of refractory psychotic disorders, with the aim of establishing therapeutic clozapine plasma levels and augmentation with other medication to improve residual symptoms. At the time of presentation, the patient’s
psychotropic medication included clozapine 700 mg daily and amisulpride 200 mg daily. His clozapine plasma level was therapeutic on admission (0.58 mg/L). His ratings on the positive and negative syndrome scale-6 (PANSS-6)34 were as follows: positive scale = 12/21 and negative scale = 18/21. Vortioxetine treatment 10 mg daily was prescribed to treat persistent negative symptoms. However, the patient showed a minimal response. Given the lack of clinical response to amisulpride treatment, this was switched to cariprazine 1.5 mg daily. The patients baseline SANS32 score was 88. Cariprazine’s dose was reduced to alternative days because of possible exacerbation of positive symptoms which resolved with dose reduction. No adverse events were noted and his weight remain unchanged. After 6 months of clozapine and cariprazine treatment, the patient displayed a moderate improvement in negative symptoms with better engagement with caregivers. His clinical improvement enabled discharge from the tertiary care setting. After 6 months of combination therapy his SANS score reduced to 62 equivalent to a 56% reduction.

Outcomes on SANS are given in Figure 1

Discussion

Our findings
Clozapine is regarded as the treatment of choice in treatment-resistant schizophrenia, although approximately 40%–70% of patients will show an inadequate response to this treatment.6 This represents a large proportion of patients who will likely continue to experience poor clinical outcomes of an already debilitating condition. To address this issue, a heightened interest has developed over the years in the augmentation of clozapine to try to improve symptom management, particularly of negative symptoms.

This report presents five cases of successful augmentation of clozapine with cariprazine for treatment-resistant negative symptoms. In all five cases, there was a reduction in negative symptoms after at least 6 months of treatment. Limitations inherent in a case series, including its retrospective nature and selection bias, are applicable in this study. Nonetheless, despite it being challenging to rate a patient’s subjective experience, the use of validated assessments for negative symptoms (SANs) by the same medical team in all our cases strengthens our findings.35 Our case series is somewhat limited by the small number of patients studied; however, to our knowledge, this is the largest naturalistic study to date on clozapine augmentation with cariprazine for residual negative symptoms. Furthermore, the lack of objective measures for treatment adherence limits our findings. This is particularly relevant as it has recently been suggested that withdrawal-associated symptoms can occur even between doses of clozapine.36,37 Therefore, it is plausible beyond other possibilities, that cariprazine augmentation may have alleviated such symptoms. Nevertheless, empirical research in this area is required.

Comparison to other studies
Interestingly, a growing body of literature has demonstrated clinical effectiveness of clozapine in combination with partial D2 agonists, particularly aripiprazole in both oral and injectable form.38–45 As can be seen in Table 2, clozapine augmentation with cariprazine for negative symptoms has not been widely studied, with evidence limited to case reports and case series.28,46 Nevertheless, the current evidence provides ground for cautious optimism. Consistent with our study, a recent case series by Berardis et al. demonstrated the effectiveness of cariprazine in combination with clozapine for the treatment of residual negative symptoms.28 In their study, the authors described two patients who’s PANSS score notably reduced along with a reduction in body weight after combination therapy. From a pharmacological perspective, Werner and Coveñas postulated that this improvement in symptoms were related to agonism of D3 receptors.19 Cariprazine’s partial agonist effect at the 5-HT1A receptor has been suggested to have a contributory antidepressant effect. Similar to our findings, there were no additional adverse effects observed with combination therapy in existing studies. In addition, there were no reported increase in body weight following combination therapy. Consistent with observations by Berardis et al., one of our patients reported a reduction in weight after combined treatment.58 While cariprazine’s effect on metabolic parameters are believed to be minimal or benign, it is difficult to be certain whether the improvement in negative symptoms in this individual was secondary to weight loss or vice versa.47,48

Clinical implications and future studies
How do the current findings impact clinical practice? Negative and cognitive symptoms represent
some of the most debilitating aspects of schizophrenia, often resulting in long-term morbidity, significant functional impairments and reduced quality of life for patients and their carers. These symptoms can broadly be divided into primary, secondary and persistent negative symptoms. This is particularly relevant to patients with treatment-resistant schizophrenia, where clozapine monotherapy has only demonstrated marginal symptom relief. While authors have rightly identified the inappropriate use of antipsychotic polypharmacy, this strategy may be warranted in some clinical situations, especially when patient safety is not compromised. Our data add to a growing body of evidence suggesting a role for cariprazine in augmenting clozapine for residual negative symptoms.

Table 2. Summary of studies reporting clozapine augmentation with cariprazine.

| Study          | n | Clozapine dose (mg) | Maximum cariprazine dose (mg) | Duration (weeks) | Reason for prescribing cariprazine | Previous augmentation strategies | Outcome Reported adverse effects |
|----------------|---|---------------------|------------------------------|-----------------|-----------------------------------|----------------------------------|---------------------------------|
| De Berardis et al. | 2 | 400                 | 3                            | 12              | Partial response with clozapine monotherapy | Amisulpride 800 mg               | Reduction in PANSS after 3 months Total score: 113–74 Positive: 22–18 Negative: 33–27 General: 58–44 | N |
|                |   | 350                 | 3                            | 12              | Partial response with clozapine monotherapy | None                             | Reduction in PANSS after 3 months Total score: 121–57 Positive: 27–9 Negative: 34–12 General: 70–29 | N |
| Aubel46        | 1 | 100                 | 3                            | 6               | Persistent negative symptoms        | Amisulpride 300 mg               | Remission of psychotic symptoms Significant improvement in psychomotor drive and mood Discontinuation of clozapine | N |

PANSS, The Positive and Negative Syndrome Scale.

Figure 1. SANS scores.
symptoms. As demonstrated by De Berardis et al.,
the addition of cariprazine to clozapine may pro-
vide scope for dose reduction of the latter to
improve tolerability.51 Furthermore, in four cases,
including existing case reports in the literature
(Table 2), cariprazine was effective where other
augmentation antipsychotics failed, including
often preferred amisulpride. This may suggest
that cariprazine is at least as equally effective as
amisulpride, which has established evidence for
augmentation purposes in clozapine-resistant
patients.52,53 However, methodologically rigorous
studies, utilising large samples and well-controlled
prospective designs is indicated to establish this.
Also, the optimal dose of cariprazine as an adjunct
to clozapine is unknown.

**Conclusion**

This case series suggests the safe and effective use
of cariprazine as an augmentation strategy in
TRS, particularly for the alleviation of negative
symptoms. However, future work, utilising larger
samples and well-controlled prospective designs are required to establish this effect.

**Conflict of interest statement**

The authors declared the following potential con-
flicts of interest with respect to the research,
authorship, and/or publication of this article:
David Taylor is the Editor-in-Chief of Therapeutic
Advances in Psychopharmacology. Therefore,
the peer review process was managed by alterna-
tive members of the Board and the submitting
Editor was not involved in the decision-making
process.

**Funding**

The authors received no financial support for the
research, authorship, and/or publication of this
article.

**Ethics statement and patient consent**

Written informed consent was obtained from the
patients for the publication of their medical data.
As this is a Case Series rather than clinical
research, an approval by ethical committee was
not required.

**ORCID iDs**

Ebenezer Oloyede https://orcid.org/0000-0003-1352-4017

Shubhra Mace https://orcid.org/0000-0001-9548-7533

Eromona Whiskey https://orcid.org/0000-0002-6146-0073

David Taylor https://orcid.org/0000-0002-2557-1710

**References**

1. Oloyede E, Casetta C, Dzahini O, et al. There
is life after the UK clozapine central non-
rechallenge database. Schizophr Bull 2021; 47:
1088–1098.

2. Kane J, Honigfeld G, Singer J, et al. Clozapine for
the treatment-resistant schizophrenic. A double-
blind comparison with chlorpromazine. Arch Gen
Psychiatry 1988; 45: 789–796.

3. Wimberley T, MacCabe JH, Laursen TM, et al.
Mortality and self-harm in association with
clozapine in treatment-resistant schizophrenia.
Am J Psychiatry 2017; 174: 990–998.

4. Cho J, Hayes RD, Jewell A, et al. Clozapine
and all-cause mortality in treatment-resistant
schizophrenia: a historical cohort study. Acta
Psychiatr Scand 2019; 139: 237–247.

5. Siskind D, Reddel T, MacCabe JH, et al. The
impact of clozapine initiation and cessation on
psychiatric hospital admissions and bed days: a
mirror image cohort study. Psychopharmacology
2019; 236: 1931–1935.

6. Siskind D, Siskind V and Kisely S. Clozapine
response rates among people with treatment-
resistant schizophrenia: data from a systematic
review and meta-analysis. Can J Psychiatry 2017;
62: 772–777.

7. Samanaite R, Gillespie A, Sendt K-V, et al. Biological
predictors of clozapine response: a systematic
review. Front Psychiatry 2018; 9: 327–327.

8. Oloyede E, Dzahini O, Whiskey E, et al. Clozapine
and norclozapine plasma levels in patients
switched between different liquid formulations.
Ther Drug Monit 2020; 42: 491–496.

9. McGlashan TH. A selective review of recent
North American long-term followup studies of
schizophrenia. Schizophr Bull 1988; 14:
515–542.

10. Revicki DA, Luce BR, Weschler JM, et al.
Cost-effectiveness of clozapine for treatment-
resistant schizophrenic patients. Hosp Community
Psychiatry 1990; 41: 850–854.

11. Davies LM and Drummond MF. Economics and
schizophrenia: the real cost. Br J Psychiatry 1994;
165(Suppl. 25): 18–21.
12. Correll CU and Schoeler NR. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. *Neuropsychiatr Dis Treat* 2020; 16: 519–534.

13. Krause M, Zhu Y, Huhn M, *et al.* Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. *Eur Arch Psychiatry Clin Neurosci* 2018; 268: 625–639.

14. Wagner E, Löhrs L, Siskind D, *et al.* Clozapine augmentation strategies – a systematic meta-review of available evidence. Treatment options for clozapine resistance. *J Psychopharmacol* 2019; 33: 423–435.

15. Fagiolini A, Alcalá JÃ, Aubel T, *et al.* Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel. *Ann Gen Psychiatry* 2020; 19: 55.

16. Stahl SM. Mechanism of action of cariprazine. *CNS Spectr* 2016; 21: 123–127.

17. Dunnett D, Oloyede E, Odunoyi O, *et al.* Evaluation of the effectiveness and acceptability of the long-acting oral antipsychotic paliperidone: illustrative case series. *J Psychopharmacol*. Epub ahead of print 27 October 2021. DOI: 10.1177/026988112111050561.

18. Caccia S, Invernizzi RW, Nobili A, *et al.* A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia. *Ther Clin Risk Manag* 2013; 9: 319–328.

19. Werner F-M and Coveñas R. The novel antipsychotic drug cariprazine and cognition enhancing drugs: indications for their use as the add-on therapy in schizophrenia. *Curr Pharm Des* 2021; 27: 4033–4038.

20. Nakamura T, Kubota T, Iwakaji A, *et al.* Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). *Drug Des Devel Ther* 2016; 10: 327–338.

21. Fleischhacker W, Galderisi S, Laszlovszky I, *et al.* The efficacy of cariprazine in negative symptoms of schizophrenia: post hoc analyses of PANSS individual items and PANSS-derived factors. *Eur Psychiatry* 2019; 58: 1–9.

22. Durgam S, Starace A, Li D, *et al.* An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. *Schizophr Res* 2014; 152: 450–457.

23. Durgam S, Cutler AJ, Lu K, *et al.* Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. *J Clin Psychiatry* 2015; 76: e1574–e1582.

24. Durgam S, Earley W, Li R, *et al.* Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. *Schizophr Res* 2016; 176: 264–271.

25. Kane JM, Zukin S, Wang Y, *et al.* Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. *J Clin Psychopharmacol* 2015; 35: 367–373.

26. Németh G, Laszlovszky I, Czobor P, *et al.* Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. *Lancet* 2017; 389: 1103–1113.

27. Weiser M, Shneider-Beeri M, Nakash N, *et al.* Improvement in cognition associated with novel antipsychotic drugs: a direct drug effect or reduction of EPS? *Schizophr Res* 2000; 46: 81–89.

28. Berardis D, Rapini G, Olivieri L, *et al.* Cariprazine add-on in inadequate clozapine response: a report on two cases. *Clin Psychopharmacol Neurosci* 2021; 19: 174–178.

29. Howes OD, McCutcheon R, Agid O, *et al.* Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. *Am J Psychiatry* 2017; 174: 216–229.

30. Guy W. ECDEU assessment manual for psychopathology. US Department of Health, Education, and Welfare, Public Health Service, Rockville, MD, 1976.

31. Hall RC. Global assessment of functioning: a modified scale. *Psychosomatics* 1995; 36: 267–275.

32. Andreasen NC. The scale for the assessment of positive and negative symptoms (SANS). *Rinsho Seishin Igaku* 1984; 13: 999–1010.

33. Van Erp TG, Preda A, Nguyen D, *et al.* Converting positive and negative symptom scores between PANSS and SAPS/SANS. *Schizophr Res* 2014; 152: 289–294.

34. Østergaard SD, Lemming OM, Mors O, *et al.* PANSS-6: a brief rating scale for the measurement of severity in schizophrenia. *Acta Psychiatr Scand* 2016; 133: 436–444.

35. Erhart SM, Marder SR and Carpenter WT. Treatment of schizophrenia negative symptoms: future prospects. *Schizophr Bull* 2006; 32: 234–237.
36. Blackman G, Oloyede E, Horowitz M, et al. Reducing the risk of withdrawal symptoms and relapse following clozapine discontinuation – is it feasible to develop evidence-based guidelines? *Schizophr Bull.* Epub ahead of print 15 October 2021. DOI: 10.1093/schbul/sbab103.

37. Blackman G and Oloyede E. Clozapine discontinuation withdrawal symptoms in schizophrenia. *Ther Adv Psychopharmacol* 2021; 11: 1–13.

38. Tiihonen J, Taipale H, Mehtälä J, et al. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. *JAMA Psychiatry* 2019; 76: 499–507.

39. Karunakaran K, Tungaraza TE and Harborne GC. Is clozapine-ariprazole combination a useful regime in the management of treatment-resistant schizophrenia? *J Psychopharmacol* 2007; 21: 453–456.

40. Englisch S and Zink M. Combined antipsychotic treatment involving clozapine and aripiprazole. *Prog Neuropsychopharmacol Biol Psychiatry* 2008; 32: 1386–1392.

41. Ziegenbein M, Wittmann G and Kropp S. Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia. *Clin Drug Investig* 2006; 26: 117–124.

42. Rocha FL and Hara C. Benefits of combining aripiprazole to clozapine: three case reports. *Prog Neuropsychopharmacol Biol Psychiatry* 2006; 30: 1167–1169.

43. Balcioglu YH, Gokcay H and Yesilkaya UH. One plus one sometimes equals more than two: long-acting injectable aripiprazole adjunction in clozapine-resistant schizophrenia. *Clin Neuropharmacol* 2020; 43: 166–168.

44. Sepede G, Di Iorio G, Spano MC, et al. A case of resistant schizophrenia successfully treated with clozapine/long-acting injectable aripiprazole combination. *Clin Neuropharmacol* 2016; 39: 322–324.

45. Souaiby L, Gauthier C, Rieu C, et al. Clozapine and long-acting injectable antipsychotic combination: a retrospective one-year mirror-image study. *Schizophr Res* 2017; 188: 89–91.

46. Aubel T. Cariprazine: patients with treatment-resistant schizophrenia. *Neuropsychiatr Dis Treat* 2021; 17: 2327–2332.

47. Bellavia A, Centorrino F, Jackson JW, et al. The role of weight gain in explaining the effects of antipsychotic drugs on positive and negative symptoms: an analysis of the CATIE schizophrenia trial. *Schizophr Res* 2019; 206: 96–102.

48. Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. *Lancet Psychiatry* 2020; 7: 64–77.

49. Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. *Schizophr Bull* 2006; 33: 1013–1022.

50. Buchanan RW, Breier A, Kirkpatrick B, et al. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. *Am J Psychiatry* 1998; 155: 751–760.

51. Taylor DM, Barnes TRE and Young AH. The Maudsley prescribing guidelines in psychiatry. Newark, NJ: John Wiley & Sons, 2018.

52. Genç Y, Taner E and Candansayar S. Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. *Adv Ther* 2007; 24: 1–13.

53. Zink M, Knopf U, Henn FA, et al. Combination of clozapine and amisulpride in treatment-resistant schizophrenia-case reports and review of the literature. *Pharmacopsychiatry* 2004; 37: 26–31.